Ventyx Biosciences (NASDAQ:VTYX) Announces Quarterly Earnings Results, Beats Estimates By $0.07 EPS

Key Points

• Ventyx Biosciences reported a quarterly loss of ($0.38) EPS, exceeding the consensus estimate of ($0.45) by $0.07.
• The company's stock rose by 19.1% to $2.81 after the earnings announcement, with a trading volume significantly higher than its average.
• Institutional ownership stands at 97.88%, with major increases in stakes from firms like AQR Capital Management and Acadian Asset Management.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) posted its earnings results on Thursday. The company reported ($0.38) earnings per share for the quarter, beating analysts' consensus estimates of ($0.45) by $0.07, Zacks reports.

Ventyx Biosciences Price Performance

Shares of VTYX stock traded up $0.27 during trading hours on Wednesday, reaching $2.90. 808,321 shares of the company traded hands, compared to its average volume of 1,406,450. Ventyx Biosciences has a 12-month low of $0.78 and a 12-month high of $3.39. The company has a market cap of $206.44 million, a P/E ratio of -1.72 and a beta of 0.97. The firm has a 50-day moving average price of $2.57 and a 200 day moving average price of $1.83.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. AQR Capital Management LLC lifted its position in shares of Ventyx Biosciences by 925.6% during the 1st quarter. AQR Capital Management LLC now owns 880,222 shares of the company's stock valued at $1,012,000 after buying an additional 794,401 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in Ventyx Biosciences by 443.8% in the 1st quarter. Acadian Asset Management LLC now owns 537,054 shares of the company's stock worth $614,000 after purchasing an additional 438,286 shares in the last quarter. Finally, Jane Street Group LLC bought a new position in Ventyx Biosciences in the 1st quarter worth approximately $56,000. 97.88% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised Ventyx Biosciences from a "sell" rating to a "hold" rating in a report on Saturday.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.